US4288627A
(en)
|
1980-02-12 |
1981-09-08 |
Phillips Petroleum Company |
Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
|
NZ202757A
(en)
|
1981-12-23 |
1985-11-08 |
Novo Industri As |
Peptides and medicaments
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
ES2113879T3
(es)
|
1990-01-24 |
1998-05-16 |
Douglas I Buckley |
Analogos de glp-1 utiles para el tratamiento de diabetes.
|
JP3110452B2
(ja)
|
1990-05-09 |
2000-11-20 |
ノボ ノルディスク アクティーゼルスカブ |
エンドグルカナーゼ酵素を含んでなるセルラーゼ調製物
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
AU7531094A
(en)
|
1993-08-24 |
1995-03-21 |
Novo Nordisk A/S |
Protracted glp-1
|
US6114304A
(en)
|
1993-09-07 |
2000-09-05 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5523449A
(en)
|
1995-05-17 |
1996-06-04 |
Bayer Corporation |
Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
|
TR199802789T2
(xx)
|
1996-06-05 |
1999-03-22 |
Boehringer Mannheim Gmbh |
Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
DE69740096D1
(de)
|
1996-08-08 |
2011-02-17 |
Amylin Pharmaceuticals Inc |
Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
|
ES2283025T3
(es)
|
1996-08-30 |
2007-10-16 |
Novo Nordisk A/S |
Derivados de glp-1.1.
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
PT929567E
(pt)
|
1996-09-09 |
2005-07-29 |
Zealand Pharma As |
Sintese em fase solida de peptidos
|
EP0932614A1
(en)
|
1996-09-09 |
1999-08-04 |
Zealand Pharmaceuticals A/S |
Peptide prodrugs containing an alpha-hydroxyacid linker
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
WO1998022577A1
(en)
|
1996-11-15 |
1998-05-28 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
ES2247676T3
(es)
|
1997-01-07 |
2006-03-01 |
Amylin Pharmaceuticals, Inc. |
Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
|
US6136784A
(en)
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
AU5850798A
(en)
|
1997-02-05 |
1998-08-26 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
WO1998050351A1
(en)
|
1997-05-07 |
1998-11-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin |
New cysteine derivatives, processes for their production, and pharmaceuticals containing them
|
JP2001513512A
(ja)
|
1997-08-08 |
2001-09-04 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規なエキセンディン作動剤化合物
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
DK1032587T4
(da)
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
BR9815670A
(pt)
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
AU1617399A
(en)
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
CA2320371C
(en)
|
1998-02-13 |
2012-01-17 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
DE69942307D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
ATE269103T1
(de)
|
1998-03-13 |
2004-07-15 |
Novo Nordisk As |
Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
|
WO1999049788A1
(en)
|
1998-03-30 |
1999-10-07 |
Focus Surgery, Inc. |
Ablation system
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
DE69941510D1
(de)
|
1998-08-10 |
2009-11-19 |
Us Gov Nat Inst Health |
Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
|
EP1119625B1
(en)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
PT1137667E
(pt)
|
1998-12-07 |
2005-02-28 |
Sod Conseils Rech Applic |
Analogos do glp-1
|
ATE460942T1
(de)
|
1999-01-14 |
2010-04-15 |
Amylin Pharmaceuticals Inc |
Exendine zur glucagon suppression
|
EP1140145B2
(en)
|
1999-01-14 |
2019-05-15 |
Amylin Pharmaceuticals, LLC |
Novel exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
WO2000055119A1
(en)
|
1999-03-17 |
2000-09-21 |
Novo Nordisk A/S |
Method for acylating peptides and novel acylating agents
|
GB0404124D0
(en)
|
2004-02-25 |
2004-03-31 |
Univ Ulster |
Antagonists of GIP
|
CA2367856C
(en)
|
1999-03-29 |
2013-10-15 |
Uutech Limited |
Analogs of gastric inhibitory peptide and their use for treatment of diabetes
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
CA2372214A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
CA2395165C
(en)
|
2000-10-20 |
2012-05-22 |
Mario Ehlers |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
AU2002346491A1
(en)
|
2001-12-19 |
2003-07-09 |
Eli Lilly And Company |
Crystalline compositions for controlling blood glucose
|
IL161848A0
(en)
|
2001-12-20 |
2005-11-20 |
Lilly Co Eli |
Insulin moldecule having protracted time action
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
EP1837031B1
(en)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
JP5685355B2
(ja)
|
2002-07-04 |
2015-03-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1および糖尿病の処置方法
|
RU2376314C2
(ru)
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
KR20050121748A
(ko)
|
2003-04-29 |
2005-12-27 |
일라이 릴리 앤드 캄파니 |
연장된 시간 작용을 갖는 인슐린 유사체
|
WO2004099246A2
(en)
|
2003-05-09 |
2004-11-18 |
Novo Nordisk A/S |
Peptides for use in treating obesity
|
US7623530B2
(en)
|
2003-11-20 |
2009-11-24 |
Nokia Corporation |
Indication of service flow termination by network control to policy decision function
|
EP1711532A4
(en)
|
2004-01-30 |
2009-09-16 |
Waratah Pharmaceuticals Inc |
USE OF A GLP-1 AGONIST WITH GASTRINIC COMPOUNDS
|
EP1718665B1
(en)
|
2004-02-11 |
2013-04-10 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
PL1817048T3
(pl)
|
2004-11-12 |
2014-07-31 |
Novo Nordisk As |
Stabilne preparaty peptydów insulinotropowych
|
EA011653B1
(ru)
*
|
2005-02-11 |
2009-04-28 |
Амилин Фармасьютикалз, Инк. |
Аналоги и гибридные полипептиды gip с избираемыми свойствами
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
EP1883419A4
(en)
|
2005-05-06 |
2010-08-04 |
Bayer Pharmaceuticals Corp |
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
|
DK1891105T3
(da)
|
2005-06-13 |
2012-07-16 |
Imp Innovations Ltd |
Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
|
DE102005034394A1
(de)
|
2005-07-22 |
2007-02-01 |
Airbus Deutschland Gmbh |
Fixierfaden zum Heften von Verstärkungsfasern
|
US20090202497A1
(en)
|
2005-08-23 |
2009-08-13 |
The General Hospital Corporation |
Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
|
ES2507098T3
(es)
|
2005-11-07 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007095737A1
(en)
|
2006-02-21 |
2007-08-30 |
Waratah Pharmaceuticals Inc. |
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
|
CA2638800A1
(en)
|
2006-02-22 |
2007-09-07 |
Merck & Co., Inc. |
Oxyntomodulin derivatives
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
ITMI20061607A1
(it)
|
2006-08-09 |
2008-02-10 |
Maria Vincenza Carriero |
Peptidi con attivita farmacologica
|
WO2008043033A2
(en)
|
2006-10-04 |
2008-04-10 |
Case Western Reserve University |
Fibrillation-resistant insulin and insulin analogues
|
NZ576260A
(en)
|
2006-11-08 |
2012-04-27 |
Zealand Pharma As |
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
|
WO2008071010A1
(en)
|
2006-12-12 |
2008-06-19 |
Waratah Pharmaceuticals Inc. |
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US8669228B2
(en)
|
2007-01-05 |
2014-03-11 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
|
GEP20135944B
(en)
|
2007-02-15 |
2013-10-25 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
FR2917552B1
(fr)
|
2007-06-15 |
2009-08-28 |
Sagem Defense Securite |
Procede de regulation de la gigue de transmission au sein d'un terminal de reception
|
JP5385266B2
(ja)
|
2007-06-15 |
2014-01-08 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
EP2025684A1
(en)
|
2007-08-15 |
2009-02-18 |
Zealand Pharma A/S |
Glucagon analogues
|
US8895694B2
(en)
|
2007-09-05 |
2014-11-25 |
Novo Nordisk A/S |
Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
|
KR101656107B1
(ko)
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
GB2455553B
(en)
|
2007-12-14 |
2012-10-24 |
Nuaire Ltd |
Motor mounting assembly for an axial fan
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
CN101970476B
(zh)
|
2008-01-09 |
2014-08-27 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的胰岛素衍生物
|
ES2613152T3
(es)
|
2008-01-09 |
2017-05-22 |
Sanofi-Aventis Deutschland Gmbh |
Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
|
WO2009129250A2
(en)
|
2008-04-14 |
2009-10-22 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
US20110195896A1
(en)
|
2008-04-22 |
2011-08-11 |
Case Western Reserve University |
Isoform-specific insulin analogues
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
BRPI0915282A2
(pt)
|
2008-06-17 |
2017-02-07 |
Univ Indiana Res & Tech Corp |
agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
|
CA2727161A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
PE20100255A1
(es)
|
2008-06-17 |
2010-04-25 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
PL219335B1
(pl)
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
EP2318432B1
(en)
|
2008-07-31 |
2015-09-02 |
Case Western Reserve University |
Halogen-stabilized insulin
|
EP2328922A4
(en)
|
2008-08-07 |
2013-01-02 |
Ipsen Pharma Sas |
ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
|
ES2561208T3
(es)
|
2008-09-12 |
2016-02-25 |
Novo Nordisk A/S |
Método de acilación de un péptido o una proteína
|
KR20150116912A
(ko)
|
2008-12-15 |
2015-10-16 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
KR20110126592A
(ko)
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
WO2010070255A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2010070253A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
US8697632B2
(en)
|
2008-12-19 |
2014-04-15 |
Indiana University Research And Technology Corporation |
Amide based insulin prodrugs
|
CN102256992B
(zh)
|
2008-12-19 |
2015-04-22 |
印第安纳大学研究及科技有限公司 |
胰岛素类似物
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
WO2010107487A2
(en)
|
2009-03-18 |
2010-09-23 |
Wu Nian |
Lipid-drug conjugates for drug delivery
|
CN101519446A
(zh)
|
2009-03-31 |
2009-09-02 |
上海一就生物医药有限公司 |
一种重组人胰岛素及其类似物的制备方法
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
ME02220B
(me)
|
2009-07-13 |
2016-02-20 |
Zealand Pharma As |
Analozi acilovanog glukagona
|
ES2625735T3
(es)
|
2009-12-16 |
2017-07-20 |
Novo Nordisk A/S |
Análogos y derivados de GLP-1
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
NZ601167A
(en)
|
2010-01-20 |
2014-12-24 |
Zealand Pharma As |
Treatment of cardiac conditions
|
EP2528618A4
(en)
*
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
EP2552952A1
(en)
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
RU2559320C2
(ru)
|
2010-03-26 |
2015-08-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
CA2797431C
(en)
|
2010-04-27 |
2016-06-21 |
Zhejiang Beta Pharma Inc. |
Glucagon-like peptide-1 analogue and use thereof
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
MX2012014961A
(es)
|
2010-06-24 |
2013-02-26 |
Zealand Pharma As |
Analogos de glucagon.
|
JP6231386B2
(ja)
|
2010-11-09 |
2017-11-15 |
ノヴォ ノルディスク アー/エス |
リンカーを有する二重アシル化されたglp−1誘導体
|
TW201247702A
(en)
|
2011-01-20 |
2012-12-01 |
Zealand Pharma As |
Use of acylated glucagon analogues
|
RU2013145013A
(ru)
|
2011-03-28 |
2015-05-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
US9790262B2
(en)
|
2011-04-05 |
2017-10-17 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
CN103619175B
(zh)
|
2011-04-12 |
2016-08-17 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
WO2012153196A2
(en)
|
2011-05-10 |
2012-11-15 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
US9453062B2
(en)
*
|
2011-06-10 |
2016-09-27 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
AR088161A1
(es)
|
2011-09-23 |
2014-05-14 |
Novo Nordisk As |
Analogos de glucagon
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
KR20140114845A
(ko)
|
2011-12-23 |
2014-09-29 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
MX356958B
(es)
|
2012-05-03 |
2018-06-20 |
Zealand Pharma As |
Análogos de péptido-2 tipo glucagón (glp-2).
|
TR201815338T4
(tr)
|
2012-05-03 |
2018-11-21 |
Zealand Pharma As |
Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
|
CA2877363A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
NZ704043A
(en)
|
2012-07-23 |
2017-07-28 |
Zealand Pharma As |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
BR112015014800A2
(pt)
|
2012-12-21 |
2017-10-10 |
Sanofi Sa |
derivados da exendina-4 funcionalizada
|
US9896495B2
(en)
|
2013-10-17 |
2018-02-20 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
BR112016016321A2
(pt)
|
2014-02-18 |
2017-10-03 |
Novo Nordisk As |
Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|